Icon

Xartemis XR - (325;7.5 mg: Tablet, Extended Release, Oral)

Oxycodone Hydrochloride and Acetaminophen Mallinckrodt
325;7.5 mg: Tablet, Extended Release, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
Management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate
Yes
****** ** *** ***** ** **** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** *, ****), '*** (***** **, ****) *** *** ************ *********. ** ****** **** **** ****** ****** ** *** ****. ******* *** **** ***** **** ** ** *** **** ******* *** *** ************ *********. ********** **** *** *** ********* ***** *** ***** ** ********* *** *** *****. ********** **** ****** *********.
Xartemis XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12
*** ****** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** ********* ** **** *** *** ********* (***** ******)
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** ** \ ** -**- ********* ** **** *** **** ** *** **, ****
******* *** \ ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : ****** (*******) ******** ************ ***** *** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** *, ****), '*** (***** **, ****)
  2. *** **, **** : ******* ******** ************ ***** *** **** ** ******.
  3. *** *, **** : ************ **** ****** (*******) **** ************ ** ******* ** '***, '***, '***, '***, '***, '***, *** '***.
  4. *** *, **** : ************ ***** * **** ******* ****** ** ******** ***** ** **.
  5. *** **, **** : ************ ***** **** ******* *** ** *** ***** **** ** **** ******* '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** **, ****), '*** (*** *, ****), '*** (***** **, ****)
  6. *** **, **** : ************ *** *** ********* ********** ** *** ****** *** ********* *** **** ** ****** ** **** ***.
  7. *** *, **** : ************ ***** *** ******* ********* ******* ****** (*******) **** ************ ** ******* ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  8. *** *, **** : ********** *** ******* **** *** ***** *** ***** ** ********** *** *** *****.
  9. *** **, **** : ************ *** ****** (*******) ******* ******** ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, *** '***. ** ****** ** ** * **********.
  10. *** **, **** : ************ ***** *** ******* ********* ******* ****** (*******) **** ************ ** ******* ** '***, '***, '***, '*** *** '***.
  11. *** **, **** : ************ *** ****** (*******) ******* ******** ****** **** ************ ** ****** ** '***, '***, '***, '*** *** '***. ** ****** ** ** * **********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.